Black Hawk Acquisition Corporation Announces Redemption Results in Connection With Its Business Combination With Vesicor Therapeutics Inc.
BLACKHAWK, Calif., Oct. 14, 2026 (GLOBE NEWSWIRE) -- Black Hawk Acquisition Corporation (NASDAQ: “BKHAU,” “BKHA,”
Press Release Disclaimer: This is a press release distributed through the XPR Media network. It has not been independently verified by our newsroom.

![]()
BLACKHAWK, Calif., Oct. 14, 2026 (GLOBE NEWSWIRE) — Black Hawk Acquisition Corporation (NASDAQ: “BKHAU,” “BKHA,” “BKHAR”) “Black Hawk” or the “Company”) today announced that, in connection with its proposed business combination (the “Business Combination”) with Vesicor Therapeutics Inc. (“Vesicor”), holders of 2,089,162 Class A ordinary shares eligible for redemption exercised their redemption rights, resulting in aggregate redemption payments of approximately $25.15 million. The redemptions relate solely to shares eligible for redemption and do not affect the Company’s other issued and outstanding Class A ordinary shares. Following the redemptions, the Company is expected to have approximately 2.06 million Class A ordinary shares issued and outstanding, including shares not subject to redemption. Based on the redemption elections, approximately $420,377 is estimated to remain in the Company’s trust account, subject to final reconciliation and adjustment.
About the Business Combination
On April 26, 2025, Vesicor Therapeutics, Inc. entered into the Business Combination Agreement, as amended. Upon closing of the Business Combination, the combined company is expected to become a publicly traded company listed on NASDAQ trading under the symbol “VESI”.
About Vesicor Therapeutics Inc.
Vesicor Therapeutics, Inc. is a preclinical-stage biotechnology company developing p53-based cancer therapeutics delivered via precision-engineered microvesicles. The company’s lead product candidate, ecm-RV/p53, uses a non-viral microvesicle platform to deliver p53 mRNA directly into cancer cells and is designed to restore tumor suppression in advanced solid tumors. Founded in 2008, Vesicor is headquartered in San Gabriel, California.
About Black Hawk Acquisition Corp.
Black Hawk is a special purpose acquisition company with a bold mission: to revolutionize the healthcare sector through a merger, stock purchase, or business combination.
Participants In the Solicitation
Black Hawk, VESICOR, and their respective directors, executive officers, other members of management, and employees may be deemed participants in the solicitation of proxies from Black Hawk’s stockholders with respect to the Business Combination. Investors and security holders may obtain more detailed information regarding the names and interests in the Business Combination of Black Hawk’s directors and officers in Black Hawk’s filings with the Securities and Exchange Commission (the “SEC”), including the preliminary proxy statement/prospectus, the definitive proxy statement/prospectus, amendments and supplements thereto, and other documents filed with the SEC. Such information with respect to VESICOR’s directors and executive officers is also included in the proxy statement/prospectus. You may obtain free copies of these documents as described below under the heading “Additional Information and Where to Find It.”
Non-Solicitation
This press release is not a proxy statement or solicitation of a proxy, consent or authorization with respect to any securities or in respect of the potential transaction and shall not constitute an offer to sell or a solicitation of an offer to buy the securities of Black Hawk or VESICOR, nor shall there be any sale of any such securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction. No offer of securities shall be made except by means of a prospectus meeting the requirements of the Securities Act of 1933, as amended.
Forward-Looking Statements
This press release includes certain statements that may be considered forward-looking statements within the meaning of the federal securities laws. Forward-looking statements include, without limitation, statements about future events or Black Hawk’s or VESICOR’s future financial or operating performance. For example, statements regarding VESICOR’s anticipated growth and the anticipated growth and other metrics, statements regarding the benefits of the Business Combination, and the anticipated timing of the completion of the Business Combination are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may,” “should,” “could,” “might,” “plan,” “possible,” “project,” “strive,” “budget,” “forecast,” “expect,” “intend,” “will,” “estimate,” “anticipate,” “believe,” “predict,” “potential” or “continue,” or the negatives of these terms or variations of them or similar terminology.
These forward-looking statements regarding future events and the future results of Black Hawk and VESICOR are based on current expectations, estimates, forecasts, and projections about the industry in which VESICOR operates, as well as the beliefs and assumptions of Black Hawk’s management and VESICOR’s management. These forward-looking statements are only predictions and are subject to, without limitation, (i) known and unknown risks, including the risks and uncertainties indicated from time to time in the final prospectus of Black Hawk relating to its initial public offering filed with the SEC, and in the proxy statement/prospectus filed by Black Hawk and VESICOR on September 22, 2026, including those under “Risk Factors” therein, and other documents filed or to be filed with the SEC by Black Hawk; (ii) uncertainties; (iii) assumptions; and (iv) other factors beyond Black Hawk’s or VESICOR’s control that are difficult to predict because they relate to events and depend on circumstances that will occur in the future. They are neither statements of historical fact nor promises or guarantees of future performance. Therefore, VESICOR’s actual results may differ materially and adversely from those expressed or implied in any forward-looking statements and Black Hawk and VESICOR therefore caution against relying on any of these forward-looking statements.
These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Black Hawk and its management and VESICOR and its management, as the case may be, are inherently uncertain and are inherently subject to risks, variability and contingencies, many of which are beyond Black Hawk’s or VESICOR’s control. Factors that may cause actual results to differ materially from current expectations include, but are not limited to: (i) the occurrence of any event, change or other circumstances that could give rise to the termination of the Business Combination Agreement and any subsequent definitive agreements with respect to the Business Combination; (ii) the outcome of any legal proceedings that may be instituted against Black Hawk, VESICOR, or others following the announcement of the Business Combination and any definitive agreements with respect thereto; (iii) the inability to complete the Business Combination due to the failure to obtain consents and approvals of the shareholders of Black Hawk, to obtain financing to complete the Business Combination or to satisfy other conditions to closing, or delays in obtaining, adverse conditions contained in, or the inability to obtain necessary regulatory approvals required to complete the transactions contemplated by the Business Combination Agreement; (iv) the failure to realize estimated shareholder redemptions, purchase price and other adjustments; and (v) other risks and uncertainties set forth in the filings by Black Hawk with the SEC. There may be additional risks that neither Black Hawk nor VESICOR presently know or that Black Hawk and VESICOR currently believe are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. Any forward-looking statements made by or on behalf of Black Hawk or VESICOR speak only as of the date they are made. None of Black Hawk or VESICOR undertakes any obligation to update any forward-looking statements to reflect any changes in their respective expectations with regard thereto or any changes in events, conditions or circumstances on which any such statement is based.
Additional Information and Where to Find It
In connection with the Business Combination Agreement, Black Hawk and VESICOR have filed a proxy statement/prospectus of Black Hawk, and will file other documents regarding the proposed transaction with the SEC. This communication is not intended to be, and is not, a substitute for the proxy statement/prospectus or any other document that Black Hawk has filed or may file with the SEC in connection with the proposed transaction. The definitive proxy statement and other relevant materials for the proposed transaction have been mailed or made available to stockholders of Black Hawk as of a record date to be established for voting on the proposed transaction.
Before making any voting or investment decision, investors and stockholders of Black Hawk are urged to carefully read the entire registration statement, the proxy statement/prospectus, and any other relevant documents filed with the SEC, as well as any amendments or supplements to these documents, and the documents incorporated by reference therein, because they will contain important information about Black Hawk, VESICOR, and the proposed transaction. Black Hawk’s investors and stockholders and other interested persons can also obtain copies of the registration statement, the preliminary proxy statement/prospectus, the definitive proxy statement/prospectus, other documents filed with the SEC that will be incorporated by reference therein, and all other relevant documents filed with the SEC by Black Hawk and/or VESICOR in connection with the transaction, without charge, once available, at the SEC’s website at www.sec.gov, or by directing a request to Black Hawk at the address set forth below.
Contact
| Vesicor Therapeutics, Inc. | Black Hawk Acquisition Corp. | |
| Luo Feng, Ph.D. Chief Executive Officer and Founder lfeng@vesicor.com |
Mr. Kent KaufmanChief Executive Officer and Chairman Email: kent@bhspac.com |
|

Media gallery
